NCT03471182 is a Phase 1 clinical trial of Psychiatric and Cognitive Testing in Cocaine Dependence, sponsored by Yale University.

Who is sponsoring NCT03471182?

NCT03471182 is sponsored by Yale University.

What drugs are being tested in NCT03471182?

Interventions in NCT03471182: Psychiatric and Cognitive Testing, Cocaine Self-adminstration, Positron Emission Tomography, Magnetic Resonance Imaging.

What condition does NCT03471182 study?

NCT03471182 studies Cocaine Dependence.

Is NCT03471182 still recruiting?

NCT03471182 is currently completed. Last updated 29 February 2024.

Are results published for NCT03471182?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-02-29 · How we verify

NCT03471182

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Investigation of Cocaine Addiction Using mGluR5 PET and fMRI

Completed Phase 1 Results posted Last updated 29 February 2024

What this trial tests

Phase 1 trial testing Psychiatric and Cognitive Testing in Cocaine Dependence in 32 participants. Completed in 18 August 2022.

Timeline

26 February 2018

Primary endpoint
18 August 2022

18 August 2022

Quick facts

Lead sponsor	Yale University
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	32
Start date	26 February 2018
Primary completion	18 August 2022
Estimated completion	18 August 2022
Sites	1 location across United States

Drugs / interventions tested

Psychiatric and Cognitive Testing
Cocaine Self-adminstration — full drug profile →
Positron Emission Tomography
Magnetic Resonance Imaging

Conditions studied

Cocaine Dependence — all drugs for Cocaine Dependence →

Sponsor

Yale University

Who can join

Adults 18 to 60, any sex, with Cocaine Dependence. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Regional Availability of Metabotropic Glutamate Type-5 Receptors (mGluR5) Primary · Following 2-5 days of cocaine abstinence

Receptor availability assessed as the volume of distribution (VT) of \[18F\]FPEB radiotracer, measured using positron emission tomography (PET). Higher \[18F\]FPEB VT values indicate a greater availability of mGluR5 receptors.

Ventral striatum

Group	Value	95% CI
Adults With a Cocaine-use Disorder (CUD)	36.48	± 8.05
Historical Healthy Comparison Adults, PET (HHC-PET)	32.19	± 5.58

Caudate

Group	Value	95% CI
Adults With a Cocaine-use Disorder (CUD)	25.67	± 7.29
Historical Healthy Comparison Adults, PET (HHC-PET)	22.41	± 4.75

Putamen

Group	Value	95% CI
Adults With a Cocaine-use Disorder (CUD)	30.31	± 5.84
Historical Healthy Comparison Adults, PET (HHC-PET)	26.06	± 5.26

Orbitofrontal cortex

Group	Value	95% CI
Adults With a Cocaine-use Disorder (CUD)	30.40	± 6.13
Historical Healthy Comparison Adults, PET (HHC-PET)	26.36	± 4.61

Anterior cingulate cortex

Group	Value	95% CI
Adults With a Cocaine-use Disorder (CUD)	32.54	± 6.88
Historical Healthy Comparison Adults, PET (HHC-PET)	28.73	± 5.54

Ventromedial prefrontal cortex

Group	Value	95% CI
Adults With a Cocaine-use Disorder (CUD)	33.95	± 7.21
Historical Healthy Comparison Adults, PET (HHC-PET)	29.41	± 5.34

Inferior frontal gyrus

Group	Value	95% CI
Adults With a Cocaine-use Disorder (CUD)	28.42	± 6.08
Historical Healthy Comparison Adults, PET (HHC-PET)	24.78	± 4.25

Middle frontal gyrus

Group	Value	95% CI
Adults With a Cocaine-use Disorder (CUD)	28.37	± 6.94
Historical Healthy Comparison Adults, PET (HHC-PET)	24.95	± 4.36

Functional Brain Network Engagement Associated With Response Inhibition Primary · Following 2-5 days of cocaine abstinence.

Independent component analysis (ICA) of functional MRI data separates brain activity associated with distinct functional networks. Comparing the activity in these networks to the fMRI task events using a regression analysis produces a beta-weight where a larger beta indicates the network was more activated or 'engaged' in processing the task demands. In this study, participants completed a Go/NoGo task to assess brain processing associated with infrequent-stimulus response inhibition (i.e., correct NoGo's) compared to frequent-stimulus responses (i.e., correct Go's).

Right frontoparietal network

Group	Value	95% CI
Adults With a Cocaine-use Disorder (CUD)	0.409	± 0.103
Healthy Comparison Adults, MRI (HC-MRI)	0.125	± 0.156

Left frontoparietal network

Group	Value	95% CI
Adults With a Cocaine-use Disorder (CUD)	0.349	± 0.159
Healthy Comparison Adults, MRI (HC-MRI)	0.037	± 0.241

Basal ganglia network

Group	Value	95% CI
Adults With a Cocaine-use Disorder (CUD)	0.175	± 0.103
Healthy Comparison Adults, MRI (HC-MRI)	-0.240	± 0.156

Cingulo-insula network

Group	Value	95% CI
Adults With a Cocaine-use Disorder (CUD)	0.103	± 0.121
Healthy Comparison Adults, MRI (HC-MRI)	-0.271	± 0.183

Resting-state Functional Brain Network Activity, Fractional Amplitude of Low-frequency Fluctuations (fALFF) Primary · Following 2-5 days of cocaine abstinence.

Independent component analysis (ICA) of functional MRI data separates brain activity associated with distinct functional networks. The fractional amplitude of low-frequency fluctuations (fALFF) during resting-state reflects a measure of the general health status of a network, comprised of both the strength of network activity and within-network connectivity absent of any specific cognitive demands.

Default-mode network

Group	Value	95% CI
Adults With a Cocaine-use Disorder (CUD)	0.747	± 0.021
Healthy Comparison Adults, MRI (HC-MRI)	0.726	± 0.030

Right frontoparietal network

Group	Value	95% CI
Adults With a Cocaine-use Disorder (CUD)	0.749	± 0.019
Healthy Comparison Adults, MRI (HC-MRI)	0.772	± 0.026

Left frontoparietal network

Group	Value	95% CI
Adults With a Cocaine-use Disorder (CUD)	0.739	± 0.021
Healthy Comparison Adults, MRI (HC-MRI)	0.734	± 0.030

Basal ganglia network

Group	Value	95% CI
Adults With a Cocaine-use Disorder (CUD)	0.636	± 0.036
Healthy Comparison Adults, MRI (HC-MRI)	0.590	± 0.051

Cingulo-insula network

Group	Value	95% CI
Adults With a Cocaine-use Disorder (CUD)	0.707	± 0.029
Healthy Comparison Adults, MRI (HC-MRI)	0.726	± 0.041

Sponsor's own description

The proposed research program will investigate the changes in brain chemistry and circuitry that 're-wire' the brain during chronic cocaine use, promote relapse, and complicate treatment efforts. Currently-using and non-treatment-seeking individuals with a cocaine use disorder will undergo a cocaine self-administration paradigm 2-5 days prior to completing positron emission tomography (PET) and functional magnetic resonance imaging (fMRI).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Cocaine self-administration behavior is associated with subcortical and cortical morphometry measures in individuals with cocaine use disorder.
Kohler RJ, Zhornitsky S, Potenza MN, Yip SW, et al · · 2024 · PMID 38551365 · DOI 10.1080/00952990.2024.2318585

Verify or expand the search:

Other recruiting trials for Cocaine Dependence

Currently open trials in the same condition.

NCT06189690 — Effect of HF rTMS on Serum BDNF in Cocaine Use Disorder · NA · recruiting

Other Yale University trials

Trials by the same sponsor.

NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03471182 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 29 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03471182.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing